Osimertinib making a breakthrough in lung cancer targeted therapy

Haijun Zhang
Department of Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, People’s Republic of China

Abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the evidence-based first-line treatment for advanced non-small-cell lung cancer that harbors sensitizing EGFR mutations (EGFRm+) such as exon 19 deletions and L858R substitutions in exon 21. However, acquired resistance to EGFR TKIs is mostly driven by a second-site EGFR T790M mutation, which negates their inhibitory activity. Osimertinib (AZD9291, Tagrisso™), an oral, third-generation EGFR TKI, has been designed to target the EGFR T790M mutation, while sparing wild-type EGFR. In this up-to-date review, focus is not only on the structure, mechanisms, and pharmacokinetics of osimertinib but also on summarizing clinical trials and making recommendations of osimertinib for patients with non-small-cell lung cancer.

Keywords: osimertinib, epidermal growth factor receptor, tyrosine kinase inhibitors, non-small cell lung cancer, T790M mutation

Introduction
Lung cancer is the leading cause of cancer-related mortality worldwide, with ∼80%–85% of patients suffering from non-small-cell lung cancer (NSCLC) and a poor prognosis for those with advanced stage disease treated with traditional chemotherapy agents.1 The discovery of genetic drivers of NSCLC has demonstrated the power of precision medicine in genetically defined tumors, and the most important drivers are mutations in EGFR gene, which occur in 10%–35% of patients with NSCLC.2-4 “Sensitizing mutations” in EGFR (EGFRm+) refer to exon 19 deletions and exon 21 L858R point mutations. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of EGFRm+ NSCLC. Patients with EGFRm+ could achieve good responses to therapy with the first-generation EGFR TKIs, such as erlotinib and gefitinib.4,4 Unfortunately, despite initial benefit, most patients develop drug resistance within 1 year, which is driven in ∼60% of cases by a second-site EGFR point mutation, the T790M mutation occurring within exon 20.7,8 However, therapeutic strategies for patients with NSCLC with the acquired resistance mediated by T790M are still limited. Although second-generation EGFR TKIs, such as afatinib, dacomitinib, and neratinib, demonstrated promising activity against T790M in preclinical models, they have failed to overcome T790M-mediated resistance in patients due to dose-limiting toxicity resulting from nonselective inhibition of wild-type EGFR.9-11 Therefore, there remains a significant need for drugs that could more effectively target T790M while sparing wild-type EGFR.12 Recently, third-generation EGFR inhibitors, including osimertinib, WZ4002, and CO-1686, have been developed and shown to be effective against cell lines and murine models harboring T790M mutations while sparing wild-type EGFR.13 These mutant-selective inhibitors could represent a promising...
approach to overcome T790M-mediated resistance in patients with NCSLC.

Osimertinib, also known as AZD9291, is a novel EGFR TKI developed by AstraZeneca, the structure and pharmacology of which are distinct from other third-generation EGFR TKIs. It shows 200-fold selectivity for T790M/L858R protein over wild-type EGFR and has been classed as a "breakthrough" compound for fast-track development, having demonstrated perfect objective response rate (ORR) in patients with T790M-positive NSCLC who had progressed on a first-generation EGFR TKI. Osimertinib received its first global approval by the US Food and Drug Administration in November 2015 for patients with metastatic EGFR T790M-positive NSCLC who had progressed on prior systemic therapy, including an EGFR TKI.

In this review, the structure, mechanisms, and pharmacokinetics (PKs) of osimertinib are addressed. Clinical trials are also summarized and recommendations are made for osimertinib for patients with NSCLC.

Structure and mechanism
Osimertinib is a mono-anilino-pyrimidine small molecule. The molecular formula for osimertinib mesylate is C_{28}H_{33}N_{7}O_{2}·CH_{4}O·S possessing a molecular weight of 596 g/mol, and its chemical name is N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2yl]amino}phenyl)prop-2-enamide mesylate salt, which is shown in Figure 1. Osimertinib binds irreversibly, via the C797 amino acid covalent bond, to certain mutant forms of EGFR (L858R, exon 19 deletion, and double mutants containing T790M) at approximately ninefold lower concentrations than to wild-type EGFR. Then, several downstream pathways, such as RAS/RAF/MAPK and PI3K/AKT, that regulate different cellular processes, including DNA synthesis and proliferation, could be inhibited, which is schematically illustrated in Figure 2. Thus, osimertinib acts as a novel and selective third-generation EGFR TKI to target the EGFR T790M mutation while sparing wild-type EGFR.

Pharmacodynamics
Osimertinib potently inhibited EGFR phosphorylation in both EGFR cells harboring EGFRm+ and T790M mutant cell lines. But it was less potent at inhibiting phosphorylation of EGFR in wild-type cell lines. IC_{50} (50% inhibiting concentration) values for exon 19 deletion and L858R/T790M are 12.92 nM and 11.44 nM, respectively, while IC_{50} for wild-type EGFR is ~493.8 nM. This implies that osimertinib could more potently inhibit phospho-EGFR of L858R, exon 19 deletion, and double mutants containing T790M compared with wild-type EGFR. AZ7550 and AZ5104 are the two pharmacologically active metabolites of osimertinib. The former has a very

Figure 1 Chemical structure of osimertinib.

Figure 2 Schematic illustration of the possible mechanism of osimertinib. 
Notes: Via the C797 amino acid covalent bond, osimertinib could target the EGFR T790M mutation while sparing wild-type EGFR, thus inhibiting several downstream pathways, such as RAS/RAF/MAPK and PI3K/AKT, that regulate different cellular processes, including DNA synthesis and proliferation.
Abbreviation: EGFR, epidermal growth factor receptor.
similar profile to osimertinib, but the latter exhibits a reduced selectivity margin against wild-type EGFR compared with the parent drug. Consistently, patients with detectable plasma levels of EGFR T790M DNA had a greater than twofold higher clinical response rate than those without detectable plasma (85% vs 33%) when osimertinib was the second-line treatment for patients with EGFRm+ NSCLC.15

**Pharmacokinetics**

Osimertinib was slowly absorbed and displayed dose-proportional increases in exposure from 20 mg to 240 mg.16,17 Distribution was extensive and clearance was low to moderate with a mean half-life of 48.3 hours. Steady state could be reached after 15 days, consistent with single-dose PK. At steady state, the Cmax to Cmin ratio of osimertinib was 1.6-fold.17 Two active metabolites, AZ7550 and AZ5104, circulated at ~10% of osimertinib exposure. Age, sex, bodyweight, ethnicity, mild or moderate renal impairment, or mild hepatic impairment does not affect the PK profile of osimertinib. Food caused a clinically insignificant increase in exposure.

**Preclinical research**

Preclinical studies have been dedicated to the antitumor activity of osimertinib in vitro and in vivo.3,11 In vitro, osimertinib potently inhibits signaling pathways and cellular growth in both EGFRm and EGFRm/T790M mutant cell line, with lower activity against wild-type EGFR lines. It also inhibits the activity of ERBB2, ERBB3, ERBBR4, ACK1, and BLK at clinically relevant concentrations. Encouraged by the in vitro remarkable inhibitory activity, the investigation of the potential antitumor effect of osimertinib in vivo was further performed. In addition, the results demonstrated that osimertinib also caused profound and sustained tumor regression in tumor xenograft and transgenic mouse models harboring activating EGFR mutations and EGFR T790M.

**Clinical trials**

The efficacy of osimertinib for the treatment of patients with locally advanced or metastatic EGFRm+ NSCLC has been investigated in several clinical trials.

**Phase I**

The Phase I AURA trial (NCT01802632) was initiated to assess the safety and efficacy of osimertinib in patients with locally advanced or metastatic EGFRm+ NSCLC who had documented disease progression while receiving a first- or second-generation EGFR TKI.16 A total of 253 patients were enrolled. The study included two cohorts: the dose-escalation cohort with 31 patients and the dose-expansion cohort with 222 patients who received oral osimertinib at five dosages of 20 mg/d, 40 mg/d, 80 mg/d, 160 mg/d, or 240 mg/d. Among 31 patients enrolled in the dose-escalation cohorts, no dose-limiting toxic effects were observed. An additional 222 patients were treated in five expansion cohorts. The ORR was 51% (95% confidence interval [CI], 45–58). Of the 127 patients with confirmed EGFR T790M, osimertinib was associated with an ORR of 61% (95% CI, 52–70), while those with no detectable EGFR T790M mutation (n=61) had an ORR of 21% (95% CI, 12–34). The median progression-free survival (PFS) was 9.6 months (95% CI, 8.3 to not reached) in EGFR T790M-positive patients and 2.8 months (95% CI, 2.1–4.3) in EGFR T790M-negative patients. Tumor response rates were similar across all osimertinib dose levels, with increasing toxicities at the 160 mg and 240 mg daily doses; thus, a dose of 80 mg daily was adopted for future studies.18 Based on these data, in April 2014, osimertinib was granted breakthrough therapy designation by the US Food and Drug Administration for the treatment of patients with NSCLC and EGFR T790M mutation whose disease has progressed during treatment with a TKI.

**Phase II**

Based on the abovementioned Phase I findings, osimertinib was further evaluated in EGFR T790M mutation-positive NSCLC patients who progressed after EGFR TKIs in a Phase II extension cohort of AURA (NCT01802632) and an additional Phase II trial (AURA2; NCT02094261). A total of 411 patients were assigned to treatment in the AURA extension trial (n=201) and the AURA2 trial (n=210). Results from a November 1, 2015, data cutoff for pooled analysis of two Phase II studies showed that ORR was 66% (95% CI, 61–71), median duration of remission was 12.5 months (95% CI: 11.1 to not calculable), median PFS was 11.0 months (95% CI: 9.6–12.4), and the proportion of patients who were progression free at 12 months was 47.5% (95% CI: 42.4–52.5).19 Thus, osimertinib received its first global approval on November 13, 2015, for patients with metastatic EGFR T790M mutation-positive NSCLC who have progressed on or after EGFR TKI therapy in the US.

**Ongoing Phase III studies**

Several Phase III trials are ongoing in evaluating osimertinib as second-line treatment for EGFR T790M-mutated NSCLC as well as first-line treatment for NSCLC with any EGFRm+. From August 2014 to December 2017, the AURA3 trial (NCT02151981), an open-label, randomized
study with a primary end point of PFS, investigates osimertinib versus platinum-based doublet chemotherapy as second-line therapy for locally advanced or metastatic NSCLC with **EGFR** T790M mutation, in which patients in the chemotherapy arm who develop progressive disease will be eligible to cross over to osimertinib treatment. The FLAURA trial (NCT02296125) from December 2014 to October 2018 is a randomized, double-blind, multinational, Phase III trial with a primary end point of PFS, which studies osimertinib versus gefitinib or erlotinib as first-line therapy in treatment-naïve patients with locally advanced or metastatic **EGFR**m+ NSCLC. For adjuvant therapy, the ADAURA trial (NCT02511106) from October 2015 to September 2021 is a randomized, double-blind, multinational Phase III trial with the primary end point of disease-free survival to compare the efficacy and safety of osimertinib with that of placebo in patients with **EGFR** mutation-positive stage I–IIIa NSCLC following complete tumor resection. Besides NSCLC, there is one clinical trial to investigate the PKs, safety, and tolerability of osimertinib in patients with advanced solid tumors and mild or moderate hepatic impairment or normal hepatic function (NCT02161770).

### Safety and side effects

Osimertinib has a good tolerability profile in patients with locally advanced or metastatic **EGFR** mutation-positive NSCLC. There were no dose-limiting toxicities observed in patients in the dose-escalation cohort of AURA at any dose level ranging from 20 mg to 240 mg daily during a 28-day evaluation period, and therefore the maximum tolerated dosage was not defined. Among the combined cohort of 253 patients in the trial, the most common adverse events included diarrhea (47%), rash (40%), nausea (22%), and decreased appetite (21%). Any adverse event of grade 3 or higher occurred in 32% of patients, of which 13% were drug related.

### Conclusion and future directions

The **EGFR** T790M mutation accounts for the majority of acquired resistance to first- and second-generation **EGFR** TKIs and represents a significant obstacle in the treatment of **EGFR**m+ advanced NSCLCs. The third-generation **EGFR**-TKIs were designed and developed to inhibit the **EGFR** T790M mutation while sparing wild-type **EGFR**, such as osimertinib, rociletinib (CO-1686), and olmutinib (HM61713). In the early-phase clinical trials, the ORRs of osimertinib, rociletinib, and olmutinib are 64%, 58%, and 29.2%, respectively. Osimertinib is a covalent third-generation **EGFR** TKI with significant activity against the **EGFR** T790M resistance mutation and common **EGFR**-activating mutations, and low activity against wild-type **EGFR**. Phase I and II studies of osimertinib have shown ORR ranging from 57% to 66% with well-tolerated profile. So far, osimertinib is the first global **EGFR** TKI approved for the treatment of NSCLC with **EGFR** T790M mutation. The main focus of academic research moving forward for osimertinib will hinge on preventing acquired resistance to monotherapy and attempting to combine osimertinib with other anticancer therapies.

### Acknowledgment

This work was supported by the National Natural Science Foundation of China (81371678).

### Disclosure

The author reports no conflicts of interest in this work.

### References


